BioCentury
ARTICLE | Finance

Onward and upward

Biotech winners, losers in 2Q17

July 7, 2017 11:40 PM UTC

The top three market cap tiers continued to outperform smaller caps in 2Q17, led by companies valued between $1 billion and $9.9 billion. Companies valued below $1 billion failed to carry over their momentum from the first quarter, with the bottom two market cap tiers both losing ground.

Large cap biotechs valued at $10 billion and up posted a median increase of 4.2% and gained nearly $47 billion in aggregate equity value (see “Results by Market Cap”). ...